Write in a clean editor, then format for PLoS Clinical Trials in one click — DocuGuru applies the official PLOS template with numbered references and exports a submission-ready PDF plus the editable LaTeX source. Free to start.
PLoS Clinical Trials is a peer-reviewed journal published by PLOS, covering Malaria Research and Control, HIV/AIDS Research and Interventions, HIV Research and Treatment.
| Publisher | PLOS |
|---|---|
| Reference style | Numbered (Vancouver) Numbered — [1], [2] in the text 1. Smith A, Jones B, Lee C. A representative article title. PLoS Clinical Trials. 2023;12(3):45–58.
Formats any DOI in PLoS Clinical Trials style. No sign-up. |
| Publishes research in | Malaria Research and Control HIV/AIDS Research and Interventions HIV Research and Treatment Meta-analysis and systematic reviews Inflammatory mediators and NSAID effects |
| ISSN | 1555-5887 |
| h-index | 32 |
| i10-index | 54 |
| Total citations | 3,675 |
| Top institutions publishing here | London School of Hygiene & Tropical Medicine |
| Journal website | www.pubmedcentral.nih.gov |
| You get | A submission-ready PDF and the editable LaTeX source — ready to submit. |
Citations each year’s papers have accumulated so far — the most recent years are still building up.
Citation: Rothwell, P. M. (2006). 'Factors that can affect the external validity of randomised controlled trials' PLoS Clinical Trials, 1(1): e9. [Available at http://clinicaltrials.ploshubs.org]. Copyright 2006 Peter M. Rothwell. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided…
OBJECTIVES: The objective of this trial was to investigate the safety and preliminary effectiveness of a daily dose of 300 mg of tenofovir disoproxil fumarate (TDF) versus placebo in preventing HIV infection in women. DESIGN: This was a phase 2, randomized, double-blind, placebo-controlled trial. SETTING: The study was conducted between June 2004 and March 2006…
OBJECTIVES: The Alzheimer's Disease Anti-inflammatory Prevention Trial (ADAPT) was designed to evaluate the conventional NSAID naproxen sodium and the selective COX-2 inhibitor celecoxib for primary prevention of Alzheimer's dementia (AD). On 17 December 2004, after the Adenoma Prevention with Celecoxib (APC) trial reported increased cardiovascular risks with celecoxib, the ADAPT Steering Committee suspended treatment and…
OBJECTIVES: To compare the efficacy and safety of artemether-lumefantrine (AL) and dihydroartemisinin-piperaquine (DP) for treating uncomplicated falciparum malaria in Uganda. DESIGN: Randomized single-blinded clinical trial. SETTING: Apac, Uganda, an area of very high malaria transmission intensity. PARTICIPANTS: Children aged 6 mo to 10 y with uncomplicated falciparum malaria. INTERVENTION: Treatment of malaria with AL or…
OBJECTIVE: The objective was to measure the efficacy of the vaccination regimen FFM ME-TRAP in preventing episodes of clinical malaria among children in a malaria endemic area. FFM ME-TRAP is sequential immunisation with two attenuated poxvirus vectors (FP9 and modified vaccinia virus Ankara), which both deliver the pre-erythrocytic malaria antigen construct multiple epitope-thrombospondin-related adhesion protein…
